Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VIVUS, Inc. (VVUS), ISIS Pharmaceuticals, Inc. (ISIS), Gilead Sciences, Inc. (GILD): Biotech Companies Battle It Out

Biotech companies sometimes get lucky, launching a drug into a new indication where there’s no competition, but more often than not the biotech companies have to battle it out with other drugmakers to reign supreme.

Here are three areas where biotech companies are facing head-to-head competition, along with some thoughts on who might ultimately win.

VIVUS, Inc. (NASDAQ:VVUS)Help from a friend
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) both launched obesity drugs within the last year.

In the short term, Arena has the clear advantage, simply because it has a larger pharma, Eisai, promoting the drug. It also doesn’t have any restrictions on sales at pharmacies. VIVUS, Inc. (NASDAQ:VVUS)’s Qsymia will only available at certified pharmacies, and it’s going to take awhile to get them all certified.

For the longer term, Qsymia could gain the upper hand, especially if it can find a marketing partner, since the drug produces better weight loss — albeit with additional potential side effects.

Of course, obesity is a large market. There’s likely room for two biotech companies to have blockbuster drugs if they can convince doctors to prescribe the drugs and insurers to pay for them.

Adopting the orphan
Both ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Aegerion Pharmaceuticals (NASDAQ:AEGR) gained approval for an orphan genetic disorder called homozygous familiar hypercholesterolemia, or HoFH.

While ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has a marketing partner in Sanofi (NYSE:SNY), that’s less of an advantage for HoFH than it is for obesity where there’s a lot more doctors seeing obese patients. Only 3,000 people in the U.S. have HoFH, so a large sales force isn’t really needed.

I think Aegerion, which is going it alone, has the advantage because its drug is so much better. Juxtapid is taken orally while ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Sanofi’s Kynamro has to be injected. Juxtapid also has less severe side effects, which should give the biotech company an advantage.

David and Goliath
Johnson & Johnson (NYSE:JNJ) may be three times the size of Gilead Sciences, Inc. (NASDAQ:GILD), but the smaller biotech company should have no problem competing with Johnson & Johnson in the hepatitis C space.

Both companies recently submitted their second-generation hepatitis C drugs and should hear back from the Food and Drug Administration by the end of the year.

Gilead Sciences, Inc. (NASDAQ:GILD)’s sofosbuvir would be approved to treat patients infected with all the different genotypes of virus, while Johnson & Johnson’s simeprevir is limited to just genotype 1 patients.

These drugs aren’t the endgame for hepatitis C. They’ll likely be used in combination with other drugs, which gives Gilead Sciences, Inc. (NASDAQ:GILD) the clear advantage because it has an extensive pipeline of additional drugs to combine with sofosbuvir. Johnson & Johnson is counting on partnerships to fill that gap.

The article Biotech Companies Battle It Out originally appeared on

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.